Lipigon Pharmaceuticals AB (publ) announced that the company has submitted an application for a clinical trial (CTA, Clinical Trial Application) to the Swedish Medical Products Agency. The application is for a permit to start a clinical phase I study with the lipid-lowering drug candidate Lipisense. The application to the Swedish Ethical Review Authority will also be submitted shortly.

The trial aims to document the safety profile of Lipisense and pharmacokinetic properties as well as pharmacodynamic effects via biomarkers.